Updated just now · Live
Stock analysis, price data, and AI-powered insights for Pliant Therapeutics Inc (PLRX).
Pliant Therapeutics Inc operates in the Pharmaceuticals sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for PLRX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). PLRX Stock Intelligence Report. [stoxpulse.com/stocks/plrx]
Disclaimer: The information on this page about Pliant Therapeutics Inc (PLRX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Pliant Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Reported Earlier, Pliant Therapeutics Announced Th...
1d ago
Pliant Therapeutics Announces Updated Data from Ph...
3d ago
StoxPulse AI results for PLRX: Pulse Score 49/100. Primary sentiment trends from 5 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$79.9M
P/E Ratio
—
EPS
$-0.43
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Reported Earlier, Pliant Therapeutics Announced The Updated Data From Its Phase 1 Trial Of PLN-101095, In Combination With Pembrolizumab, In Patients With Immune Checkpoint Inhibitor (ICI)-refractory Advanced Or Metastatic Solid Tumors
Pliant Therapeutics Announces Updated Data from Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics : Final AACR 2026 PLN10195 Yap
Pliant Therapeutics says PLN-101095 generally well tolerated; most common TRAE was rash, one grade 3 TRAE observed
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting